Epstein Barr Virus-Encoded EBNA1 Interference with MHC Class I Antigen Presentation Reveals a Close Correlation between mRNA Translation Initiation and Antigen Presentation by Apcher, Sebastien et al.
Epstein Barr Virus-Encoded EBNA1 Interference with
MHC Class I Antigen Presentation Reveals a Close
Correlation between mRNA Translation Initiation and
Antigen Presentation
Sebastien Apcher
1, Chrysoula Daskalogianni
1, Benedicte Manoury
2, Robin Fa ˚hraeus
1*
1Cibles The ´rapeutiques, INSERM U940, Institut de Ge ´ne ´tique Mole ´culaire, Universite ´ Paris 7, Ho ˆpital St. Louis, Paris, France, 2Institute Curie, Paris, France
Abstract
Viruses are known to employ different strategies to manipulate the major histocompatibility (MHC) class I antigen
presentation pathway to avoid recognition of the infected host cell by the immune system. However, viral control of
antigen presentation via the processes that supply and select antigenic peptide precursors is yet relatively unknown. The
Epstein-Barr virus (EBV)-encoded EBNA1 is expressed in all EBV-infected cells, but the immune system fails to detect and
destroy EBV-carrying host cells. This immune evasion has been attributed to the capacity of a Gly-Ala repeat (GAr) within
EBNA1 to inhibit MHC class I restricted antigen presentation. Here we demonstrate that suppression of mRNA translation
initiation by the GAr in cis is sufficient and necessary to prevent presentation of antigenic peptides from mRNAs to which it
is fused. Furthermore, we demonstrate a direct correlation between the rate of translation initiation and MHC class I antigen
presentation from a certain mRNA. These results support the idea that mRNAs, and not the encoded full length proteins, are
used for MHC class I restricted immune surveillance. This offers an additional view on the role of virus-mediated control of
mRNA translation initiation and of the mechanisms that control MHC class I restricted antigen presentation in general.
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Introduction
Presentation of antigenic peptides on major histocompatibility
(MHC) class I molecules is a signal for CD8
+ T cells to distinguish
between cells that express self or non-self antigens and forms an
important part of the immune system’s capacity to fight parasite
invasion. There are several steps that endogenous peptides pass
from their synthesis to the loading onto the MHC class I molecule.
On one hand, the digestion of the peptide precursor by the
proteasome [1,2,3], the affinity of the peptide for the TAP
transporter [4], the trimming of the N-terminus by endopeptidases
[5] and the sequence requirements of the peptide to fit the grove
on the MHC class I molecules [6], are all important steps in
determining the efficiency of peptide presentation. On the other
hand, the steps prior to the digestion of the peptide precursor by
the proteasome, the so called pre-proteasomal steps, have to
ensure that enough peptide material is produced so that a
sufficient amount of the correct peptide epitopes reaches the class I
molecules in order to trigger a T cell response. It has been
estimated that approximately 10
4–10
5 MHC class I molecules are
expressed by individual cells at any time to ensure a sufficient
antigen presentation.
Proteins and polypeptides exhibit a wide range of half-life, with
an overall average of 1 to 2 days [7]. As the stability of viral
proteins is many times high, it would take many hours for the cells
to accumulate a sufficient amount of viral peptides to trigger the
most efficient T-cell response if these were derived from the
degradation of the full length protein. To explain the rapidity of
viral-antigen presentation, a model has been proposed in which a
fraction of rapidly degraded mRNA translation products (RDPs)
[8] or defective ribosomal products (DRiPs) [9] with a half-life of
less than 10 minutes constitute the main source for antigenic
peptides. This model has been supported by the rapid slow down
of TAP system by blocking protein synthesis and the equal rapid
suppression of antigen presentation when transcription of an
mRNA encoding a protein with a long half life is shut off [10]. In
addition, cryptic mRNA translation products derived from
different reading frames throughout the message can provide
substrates for the MHC class I pathway [11]. The use of
alternative translation products as a source for antigenic peptides,
together with the fact that continues ribosomal activity is required
for antigen presentation, implicates mRNA translation as an
important pre-proteasomal step in regulating MHC class I
restricted antigen presentation. However, the translation mecha-
nisms that govern the synthesis of antigenic peptide products are
unknown.
Viruses adapt to their environment and manipulate their host
cells in order to serve their needs. Controlling the MHC class I
antigen presentation pathway is an important target for latent
viruses in order to avoid detection of the infected host cell by the
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whereby viral products target the MHC class I pathway on the
post-proteasomal level [12,13] but there is so far little known about
how viruses affect the steps that control the production of antigenic
peptides. The Epstein-Barr virus (EBV) expresses the nuclear
antigen-1 (EBNA1) in all types of infected cells and in its type I
latent form, e.g. observed in Burkitt’s lymphoma, it is the only viral
antigen detected [14]. A Glycine-Alanine repeat sequence (GAr)
located in the N-terminal part of EBNA1 with no apparent
biochemical function has a cis-acting capacity to suppress
presentation of antigenic peptides to the MHC class I pathway
and plays an important role for the EBV to evade immune
detection [15,16]. Like EBNA1, Kaposi’s sarcoma-associated
herpesvirus LANA1 protein and the MHV-68 gamma herpes
virus ORF73 are latent origin binding proteins that act for
maintaining viral episomes in infected cells. These two proteins
have more recently been suggested to use a similar strategy, but
with different sequences, as EBNA1 to escape the MHC class I
pathway [17,18], indicating that this might be a more commonly
used concept among viruses to evade the immune system.
It was recently shown that the nascent GAr peptide targets the
initiation step of translation of any mRNA to which it is fused [19].
Here we have used GAr-mediated control of mRNA translation
initiation to study its effect on MHC class I restricted antigen
presentation. By manipulating the GAr sequence we can control
the rate of translation initiation of a reporter mRNA in cis and we
can thereby demonstrate that the rate of translation initiation, as
opposed to other means of translation control, directly determines
the amount of presented peptides derived from the main open
reading frame as well as from cryptic translation products of a
given mRNA. We discuss how these results fit together with the
concept of EBNA1 as an immunologically silent protein and the
proposed models for the source of antigenic peptide material for
the MHC class I pathway.
Results
Direct influence of a Gly-Ala repeat on the presentation
of a reporter epitope
The Gly-Ala repeat sequence (GAr) of EBNA1 can prevent
mRNA translation initiation and MHC class I restricted antigen
presentation from open reading frames (ORF) to which it is fused
[19,20]. To test to which degree the GAr is responsible for the
suppression of EBNA1 antigen presentation we fused the
SIINFEKL encoding antigenic peptide sequence (SL8) derived
from chicken Ovalbumin (Ova) [21,22] into the EBNA1 (EBNA1-
SL8) or in an EBNA1 in which the Gly-Ala repeat (GAr) was
deleted (EBNA1DGA-SL8) (Fig. 1A). This allowed us to monitor
any effect the GAr has on antigen presentation from these mRNAs
using the B3Z CD8
+ T hybridoma that is specific for the SL8 in
the context of H-2K
b MHC class I molecules [23].
H-2K
b EL4 cells expressing Ova or EBNA1DGA-SL8 gave a
similar level of presentation of the SL8 epitope, demonstrating that
there is no significant difference in how this antigen is processed
and presented between these two constructs. However, presenta-
tion of SL8 in the context of EBNA1 was dramatically suppressed
and comparable to cells expressing an empty vector (Fig. 1B, left
graph). Similar results were obtained using the H1299 human cell
line in which a vector coding the mouse H-2K
b MHC class I
molecule was cotransfected together with the expression vectors
for Ova, EBNA1-SL8 or EBNA1DGA-SL8 respectively (Fig. 1B,
right graph).
To test how this difference in antigen presentation correlates
with GAr’s inhibitory effect on protein synthesis, H1299 cells
expressing each construct were pulsed for 1 h in the presence of
35S-methionine and proteasome inhibitor in order to minimize any
effects of proteasomal degradation before harvested. This revealed
that EBNA1-SL8 is translated with approximately 60% reduced
efficiency as compared to the EBNA1DGA-SL8 (Fig. 1C). Western
blot analysis showed that the steady state protein expressions of the
respective proteins correlate with their respective rate of synthesis
(Fig. 1D).
Similar results in terms of control of synthesis and antigen
presentation were also obtained when the GAr sequence was fused
to the N-terminus of Ova itself. Fusion of the full length GAr to the
N-terminus of ovalbumin (GAr-Ova) effectively prevents the
presentation of the SL8 peptide over a wide range of mRNA
concentrations and eight times the amount of a GAr-Ova cDNA
was required to reach the same level of antigen presentation as
from cells expressing Ova alone (Fig. 1E, left panel). To ensure
that the antigen presentation reporter system was not saturated
under these conditions we increased the number of Ova expressing
EL4 cells that were exposed to the same fixed number (5610
4)o f
B3Z cells used in the above experiments (Fig. 1E, right panel).
These results, together with previous reports, collectively
support the notion that the GAr domain alone inhibits
presentation of peptides to the MHC class I pathway from the
EBNA1 or from any mRNA to which it is fused, irrespectively of
location [19,20].
The GAr suppresses presentation of antigenic peptides
throughout the entire mRNA
It is known that the GAr in addition to preventing translation
initiation also has the capacity to inhibit protein unfolding and
proteasome-mediated degradation in a substrate- and position-
dependent fashion [24]. In order to investigate if the capacity of
the GAr to affect protein stability plays a role in its capacity to
provide immune evasion we separated its two functions.
The SL8 was inserted in the 39 untranslated region (UTR) of the
GAr sequence, either in the same or in a different reading frame
(GAr-1 and GAr-2, respectively) where it is expressed as a cryptic
minigene [25,26]. Thus, any effect the GAr has on antigen
presentation from these mRNAs can be separated from its
capacity to inhibit proteasomal degradation since the GAr and
the SL8 epitope are expressed as separate polypeptides. We also
fused the SL8 peptide in frame with the C-terminus of the GAr
(GAr-3) (Fig. 2A). In addition, we made the corresponding
constructs where we exchanged the GAr sequence for that of the
GFP (GFP-1, GFP-2 and GFP-3 respectively) (Fig. 2A). The GFP
is a suitable replacement for the GAr as it is also a protein with a
low turnover rate, a poor substrate for the proteasomes [27] and,
Author Summary
The presentation of short peptides on major histocom-
patibility (MHC) class I molecules forms the cornerstone for
which the immune system tells apart self from non-self. It
is important for viruses such as the Epstein-Barr virus (EBV)
to avoid this antigen presentation pathway in order to
escape recognition and killing of its host cells. All EBV-
infected cells, including cancer cells, express EBNA1
without attracting the attention of the immune system.
In this report we describe the mechanism by which EBNA1
escapes antigen presentation. This should open up for
new approaches to target EBV-associated diseases includ-
ing cancers and immuno proliferative disorders and for
understanding the underlying mechanisms of the source
and regulation of antigenic peptide production.
Translation Initiation Controls MHC I Presentation
PLoS Pathogens | www.plospathogens.org 2 October 2010 | Volume 6 | Issue 10 | e1001151Figure 1. Inhibition of EBNA1 synthesis prevents presentation of peptides derived from the EBNA1 mRNA. A) Cartoon illustrating the
different constructs. The location of the exogenous antigenic peptide sequence SIINFEKL (SL8) of the chicken ovalbumin (Ova) in the EBNA1-SL8 and
the EBNA1DGA-SL8 constructs is indicated. B) The presentation of SL8 peptide on endogenous MHC class I K
b molecules on (0.5610
5) EL4 cells (left)
or on human cells co-expressing a genomic K
b construct (right) was determined using B3Z CD8
+ T cells [23]. The GAr domain suppresses presentation
of SL8 by over 90% in either cell type. C) Autoradiograph of a 1 hour
35S-methionine pulse label in the presence of proteasome inhibitors shows that
Translation Initiation Controls MHC I Presentation
PLoS Pathogens | www.plospathogens.org 3 October 2010 | Volume 6 | Issue 10 | e1001151importantly, the levels of mRNAs expressing the SL8 are similar in
the context of either ORF (Fig. 2B). These different constructs
allowed us to compare the effect of the GAr on suppressing MHC
class I antigen presentation independently of its capacity to
influence protein degradation. The level of presentation of SL8
from the GFP-3 is similar to that from Ova itself, demonstrating
that there is no significant difference in how the antigen is
processed in these two settings. However, presentation of the SL8
in the context of all GAr-carrying mRNAs is suppressed as
compared with the corresponding GFP constructs, demonstrating
that the GAr prevents mRNA antigen presentation throughout the
entire mRNA (Fig. 2C). The GFP-1 and GFP-2 constructs give a
lower level of presentation of the SL8 compared to when fused to
the C-terminus of GFP (GFP-3) (Fig. 2C). This is explained by the
fact that the antigenic peptide in GFP-1 and 2 are expressed as
cryptic translation products compared with when it is fused to the
main reading frame in GFP-3 and Ova. To ensure that the
expression of SL8 from the GFP-2 and GAr-2 minigene constructs
are indeed derived from an initiation event and not from a read-
through from the main ORF we substituted the AUG codon with
GGC or GCC. As this completely prevented antigen expression
from either constructs it shows that the expression of the SL8 is not
due to a read-through event and, thus, that the GAr suppresses a
reinitiating event (Fig. 2D). Western blot analysis confirms that the
expression levels from the main ORF of the different constructs
are similar (Fig. 2E). The notion that SL8 expressed from the
39UTR is derived from an independent initiation event is further
supported by treating cells with IFNc. IFNc stimulates the
induction of immunoproteasomes and N-terminal trimming
peptidases that together give a more efficient processing of
peptides longer than 8–10 residues for loading onto MHC class
I molecules [28,29]. IFNc treatment does not affect presentation of
the SL8 when inserted in the 39UTR, which is what is expected if
it is expressed as a minigene, and only when fused directly to the
C-terminus of GFP or GAr (Fig. 2F, left panel). By treating cells
with the proteasome inhibitor epoxomicin we observed that that
presentation of SL8 is proteasome-dependent when derived from
Ova, or fused to GFP, but not when translated as an out-of-frame
minigene downstream of GFP (GFP-1 &-2) (Fig. 2F, right panel) or
GAr (GAr-1 &-2) (data not shown). These results show that the
cryptic translated SL8 peptides are derived from independent
translation initiation and do not carry additional residues from the
main upstream reading frame that could interfere with the
processing of the MHC class I peptide.
Taken together, these results show that the GAr suppresses the
presentation of the SL8 epitope within the same reading frame and
out-of-frame epitopes. Hence, the GAr suppresses MHC class I
restricted antigen presentation by preventing translation initiation
throughout the entire mRNA and its potential capacity to control
protein stability is not required to impose immune evasion.
Altering mRNA translation initiation overrides the effect
of the GAr
The nascent GAr peptide is regulating the synthesis of EBNA1
by directly blocking initiation of the EBNA1 mRNA translation in
cis which is caused by a delay in the assembly of the initiation
complex [19]. The molecular target of the GAr is not yet known
but we have observed that insertion of the c-myc IRES [30] in the
59UTR of GAr-Ova (c-myc-GAr-Ova) overrides GAr-dependent
inhibition of protein synthesis and restores the rate of expression to
approximately 70% of that of Ova alone (Figs. 3A and 3B, left
panel). Similarly, the c-myc IRES also induced the expression of
the GAr alone approximately 3-fold, demonstrating that this effect
is restricted to the GAr itself (Fig. 3B, right panel). The c-myc
IRES has no effect on the rate of Ova synthesis when inserted in
an identical way in the 59UTR (Fig. 3B, left panel), indicating its
specific effect on GAr-mediated translation control. Moreover, the
c-myc IRES and the GAr domain only affect mRNA translation in
cis as we do not see any changes on the rate of translation of actin
or of the exogenous GFP (Fig. 3C).
Thus, the combination of the GAr and the c-myc IRES
provides us with tools with which we can study the relationship
between the rate of mRNA translation initiation and the
production of antigenic peptides from a single mRNA without
targeting protein synthesis or degradation using general chemical
inhibitors. When we tested the effect of the c-myc IRES on GAr-
dependent control of antigen presentation we observed a 70%
presentation of SL8, as compared to Ova alone or c-myc-Ova
(Fig. 3D). Under the same conditions the presentation of SL8 from
the GAr-Ova fusion construct was approximately 5-fold less. As
the c-myc IRES does not affect the GAr-Ova ORF this result
further underlines that the potential effect of the GAr to control
the stability of the protein to which it is fused is not sufficient to
suppress antigen presentation. Insertion of the c-myc IRES in the
59UTR of the GAr-2 mRNAs also resulted in a sharp increase in
antigen presentation, demonstrating that the same mechanism of
translation initiation control that regulates the production of
antigenic peptides derived from the main ORF also regulates the
production peptides derived from cryptic minigenes.
The capacity of the c-myc IRES to neutralise the translation
inhibitory effect of the GAr is cell specific and was observed in
three out of three human cell lines tested (Table 1). However, it
has been shown that the efficiency of the c-myc IRES-driven
translation varies between cell lines from different origins. In
murine cell lines the c-myc IRES-driven translation is much lower
than in human cell lines and importantly it has been shown to be
inactive in murine adult tissue [31,32]. This explains the finding
that the c-myc IRES was incapable to override the translation
inhibitory effect of the GAr in all the murine cell lines tested
(Table 1).
The c-myc IRES has been characterised and consists of
different domains and predicted ribosome entry window (Figs. 4A
and 4B). It has been shown that deletion of the domain 1 reduces
its activity with about 60% [33]. In line with this, fusion of a c-myc
IRES, that lacks domain 1 (Dcmyc-IRES), in the 59UTR of Ova-
GAr results in a reduced capacity to override suppression of
translation and antigen presentation (Fig. 4C). This further links
the effect of the c-myc IRES and its capacity to overcome GAr-
dependent suppression with its capacity to control mRNA
translation initiation (Fig. 4C).
These results show that GAr-mediated suppression of transla-
tion initiation is sufficient and necessary to prevent antigen
the EBNA1-SL8 mRNA is translated 60% less efficiently as compared with the EBNA1DGA-SL8. The graph below shows values determined from
phosphoimager analysis. D) Western blot shows the steady state level of expression of indicated constructs without proteasome inhibitors. E) Dose-
response curve shows that approximately 8 mg of GAr-Ova cDNA is required to reach a similar level of SL8 presentation as that of 1 mg of Ova (left
panel). Increasing number of EL4 cells expressing indicated constructs in the presence of a fixed amount (5610
4) of B3Z (right graph). The results
show representative data from at least three independent experiments in which transfected cells were split and tested for protein synthesis or
antigen presentation with SD.
doi:10.1371/journal.ppat.1001151.g001
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PLoS Pathogens | www.plospathogens.org 4 October 2010 | Volume 6 | Issue 10 | e1001151Figure 2. Inhibition of protein degradation is not essential for the GAr sequence to prevent endogenous antigen presentation for
the MHC class I restricted pathway. A) The SL8 epitope was inserted in the 39UTR of the GAr open reading frame (ORF) (GAr-1), in another
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translation products and that its effect can be neutralised by
alternative mechanisms of initiation provided by the c-myc IRES.
The rate of mRNA translation initiation directly
determines antigen presentation
The observations that the increase in rate of synthesis after
insertion of the c-myc-IRES corresponds to antigen presentation
indicates a close correlation between the rate of mRNA translation
initiation and the capacity of CD8
+ T cells to detect and destroy
virus-infected host cells. In order to look more closely at this
relationship, we wanted to change the rate of Ova synthesis more
subtly compared with the ‘‘on/off’’ effect obtained with the c-myc-
IRES and we used mutated GAr sequences that have been shown
to affect the synthesis of GAr fusion proteins. The lymphocrypto-
Papio and the Rhesus viruses infect Old World primates and
express EBNA1 homologues that carry shorter GAr-like sequences
that have previously been shown not to prevent antigen
presentation [34]. The EBV-GAr sequence consists of single
alanine residues separated by one, two or three glycines while the
Papio-GAr carries single serine residues inserted in every seven
residues of the repeat (Fig. 5A and [19]). When we fused a 30
amino acid Papio-GAr sequence (30GAr-Papio-Ova) and a
corresponding 30 amino acid EBV-GAr sequence (30GAr-EBV-
Ova) to the N-terminus of Ova we observed that the Papio-GAr-
like sequence had no effect on mRNA translation or antigen
presentation while insertion of the corresponding EBV-GAr
sequence resulted in an approximately 4-fold less synthesis and
antigen presentation (Figs. 5B and 5C). Similar results were also
obtained with the Rhesus GAr-like sequence which also carries
serine insertions (data not shown). Interestingly, the Papio-GAr
has the capacity to control protein stability and fusion of the
Papio-GAr to the p53 protein, which is normally targeted for the
ubiquitin-dependent degradation pathway by the MDM2 E3
ligase, resulted in a stabilisation and in an accumulation of
polyubiquitinated 30GAr-Papio-p53 products in the presence of
MDM2 (Fig. 5D). This indicates that while the Papio sequence
retains the effect on proteins stability, the disruption of its GAr
sequence is sufficient to render it inefficient in preventing antigen
presentation or protein synthesis control [24].
We next tested a construct in which the GAr repeat had been
disrupted by inserting two alanines next to each other on three
locations (32GAr3A-Ova) (Fig. 5E). This retains the GC rich
content of the GAr RNA sequence without introducing new
amino acid residues. In this case, the rate of synthesis was
approximately 50% less compared with Ova alone but over two-
fold more efficient than that of the wild type GAr (30GAr-EBV-
Ova) (Fig. 5F, left panel). If two glycine residues were instead
replaced by serines (31GAr2S-Ova) we obtained a 75% translation
efficiency as compared to Ova alone. When we next compared the
effects of these GAr sequences on antigen presentation we
observed that the rate of mRNA translation initiation is closely
followed by the amount of antigens presented to the MHC class I
molecules (Fig. 5F, right panel).
Taken together, these results indicate a direct and proportional
relationship between endogenous antigen presentation and mRNA
translation initiation control.
Discussion
Our results further underline the notion that the capacity of
EBNA1 to evade the MHC class I antigen presentation pathway
and the detection by CD8
+ T cells relies on the Glycine-Alanine
repeat (GAr) sequence [15,16,20,35]. Deletion of the GAr
sequence from EBNA1-SL8 resulted in the same amount of
antigen presentation as when SL8 was presented from the Ova
message indicating that no other regions of EBNA1 are needed to
evade MHC class I antigen presentation. Dose-response experi-
ments show that this effect is not dependent on the amount of
mRNA expressed in the cells and that at least eight times the
amount of a GAr-carrying mRNA is required in order to reach a
similar level of antigen presentation as that of a corresponding
non-GAr carrying mRNA.
The GAr has the unique dual capacity to suppress both its own
mRNA translation initiation as well as the stability of proteins to
which it is fused. By separating these two functions from each
other we have shown that the GAr suppresses peptide production
from different reading frames of an mRNA to which it is fused
and, hence, that control of mRNA translation initiation is both
sufficient and necessary for its capacity to suppress MHC class I
antigen presentation (Fig. 6). Previous studies have shown that the
GAr can prevent unfolding of substrates targeted for the 26S
proteasome by affecting 19S-dependent unfolding in a substrate
and position-dependent fashion. However, the GAr has no, or
little, effect on the stability of EBNA1 itself, suggesting that fusion
of GAr to 26S proteasome substrates gives unspecific effects on
protein stability that are unlikely to play any physiological role for
the virus [24]. These observations together with our results instead
support a model in which the cis-mediated effect of the GAr on
EBNA1 mRNA translation initiation is the sole mechanism by
which EBNA1-expressing latently EBV-infected cells can evade
recognition by the immune system. However, this does not mean
that EBNA1 stability is not an important feature in EBV’s strategy
to evade the immune system for the simple reason that a low rate
of EBNA1 synthesis requires a low turnover rate in order to allow
a sufficient amount of EBNA1 to be expressed (Fig. 6). The
expression of EBNA1 in the host resting B memory cells, as
compared to rapidly proliferating BL cells, is likely less, which
could further contribute to help the virus to establish an immune
evasive latency.
reading frame (GAr-2) or fused to GAr (GAr-3). The corresponding constructs were also made in which the SL8 was inserted in the GFP mRNA in an
identical way (GFP-1 to 3). The AUG, GCC or GGC initiation codons for SL8 in GAr-2 were used. B) Northern blot analysis using the SL8 sequence as
probe shows that the GAr sequence does not influence the expression levels of the corresponding mRNAs. C) The GAr suppresses presentation of SL8
throughout the entire mRNA, demonstrating that its capacity to prevent antigen presentation does not depend on controlling protein degradation.
D) Changing the initiation codon of the SL8 from AUG to GGC (Glycine) or GCC (Alanine) in the GAr-2 prevents expression and antigen presentation,
demonstrating that the SL8 is derived from an individual translation initiation event. Presentation of SL8 expressed as a minigene using the initiation
codons AUG, GGC and GCC (SL8AUG, SL8GGC and SL8GCC, respectively). E) Western blot shows the steady state level of expression of indicated
constructs (GAr-1 to 3 and GFP-1 to 3). F) IFNc stimulates antigen presentation by optimising processing of peptides longer than 8–10 residues and
has only an effect on antigen presentation when SL8 is expressed in the main ORF and not when expressed as cryptic peptide in an alternative
reading frame (left graph). Epoxomicin is a specific proteasome inhibitor and prevents presentation of SL8 when expressed in the main ORF (right
graph). This shows that expression of the SL8 epitope as a cryptic peptide does not carry additional residues from the main reading frame. Data are
representative of three or more independent experiments and values are shown with SD. Protein synthesis and antigen presentation data are derived
from cells transfected with the indicated constructs before split and tested separately.
doi:10.1371/journal.ppat.1001151.g002
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PLoS Pathogens | www.plospathogens.org 6 October 2010 | Volume 6 | Issue 10 | e1001151Figure 3. GAr suppresses antigen presentation by targeting the mRNA translation initiation process. A) Cartoon illustrating the c-myc
Internal Ribosomal Entry Sites (IRES) constructs. IRESs offer alternative cap-independent mechanisms of mRNA translation initiation. B)
Autoradiograph of
35S-methionine metabolic pulse labelling. Insertion of the c-myc IRES in the 59UTR of the GAr-Ova mRNA (c-myc-GAr-Ova)
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mRNA translation, and not prevention of elongation, is the key
feature for the GAr domain in controlling MHC class I antigen
presentation. Firstly, the insertion of the c-myc IRES in the
59UTR of GAr-carrying mRNAs prevents the GAr from
suppressing mRNA translation and antigen presentation. It is
unlikely that the insertion of an IRES in the 59UTR without any
changes to the main reading frame could impose differences in
GAr-dependent control of synthesis other than via altering the
initiation conditions. This is further supported by the observations
that deletion of the domain 1 of the c-myc IRES prevents its effect
on overcoming the GAr and its cell line-dependent mode of action.
This might also indicate that the target factor of the GAr is
independently recruited to the polysome by domain I and could
further help to elucidate the mechanisms of GAr action on
translation initiation. Secondly, the GAr-like sequence derived
from the Papio virus, where a single serine residue is inserted at
every seven amino acids, has little effect on the rate of protein
synthesis or on antigen presentation. Furthermore, by inserting
three alanines into the EBV-GAr sequence we retain the GC rich
mRNA sequence but increase synthesis and antigen presentation.
Finally, the GAr suppresses presentation of antigenic peptides that
are derived from independent translation initiation events in the
39UTR of the GAr-encoding reading frame. The latter type of
translation initiation of cryptic minigenes was shown by the group
of Shastri to be sufficient to provide antigenic peptides for the
MHC class I pathway [25]. It is difficult to see how pre-
termination of the translation due to difficulties for the ribosome in
reading through the GC rich region could explain suppression of
independent down-stream initiation events [36]. In addition,
truncated EBNA1 peptides due to failure of elongation are not
observed in EBV infected cells. Taken together, neither of the
observations presented here are likely to occur if the GAr acts via
mechanisms related to elongation, including difficult ribosomal
read-through, codon exhaustion, or other more specific mecha-
nisms [36,37]. Previous studies have shown that changes to the
GAr peptide sequence, but not RNA sequence impair its efficiency
to suppress translation [19], underlining that the effect is mediated
by the peptide, and not the RNA sequence. The GAr is predicted
to be unstructured and does not included charged residues and, as
expected, a 30 amino acid GAr peptide was found not to bind the
EBNA1 mRNA ([20] and data not shown). However, a recent
report suggests that the Gly-Arg repeat of EBNA1 has RNA
binding capacity [38].
Blocking translation initiation offers an explanation to how the
GAr can succeed in suppressing production of DRiPs/RDPs and
thus antigenic peptides derived from initiation events from all
reading frames throughout the mRNA. Based on the model that
antigenic peptides are not derived from degradation of full length
proteins it should not be possible for the GAr to avoid presentation
of peptides derived from EBNA1 by controlling its turnover rate
since this would only affect peptides derived from the full length
EBNA1 and not DRiPs [39] or RDP products that do not carry
the GAr. Our previous work and toeprint analysis carried out by
others indicate that the GAr peptide has to be synthesised in order
to suppress mRNA translation initiation and that it does not affect
the site of initiation [19,36]. This is line with the notion that the
GAr would not give rise to truncated EBNA1 peptides due to
alternative initiation sites or diffuse pre-termination events that
would not serve the function of the protein and thereby not
support viral replication, nor prevent presentation of upstream
antigenic peptides, but to an overall suppression of translation
in cis. In fact, using GAr specific polyclonal sera one does not see
any massive accumulation of truncated EBNA1 products in
normal EBV-infected cells that would have been expected from a
pre-termination event derived from within the GAr sequence.
One question that arises from this study is if this mechanism of
evading the immune system is efficient, it should be adapted by
other viruses. It has recently been suggested that the MHV-68
gamma herpes virus ORF73 is using a similar mechanism as
EBNA1 to evade MHC class I restricted antigen presentation. In
this case, however, the sequence is not identical to the GAr,
restores translation in H1299 cells but does not affect translation when inserted in the 59UTR of Ova alone (left panel). Western blot shows that the
effect of the c-myc IRES is restricted to the GAr alone (right panel). C) Autoradiograph of a 30 minutes
35S-metabolic pulse label experiment of the
endogenous protein (actin) and the exogenous GFP protein in H1299 cells in the presence of the c-myc IRES and the GAr constructs. D) The c-myc
IRES stimulates SL8 presentation in the context of the GAr from the main open reading frame as well as cryptic translated products (see Fig. 2A). Data
are representative of three or more independent experiments plus SD.
doi:10.1371/journal.ppat.1001151.g003
Table 1. GAr-dependent inhibition of antigen presentation in different cell lines from different origins.
Cell line Cell Origin
(%) antigen presentation as compared
to Ova or EBNA1DGA
(%) antigen presentation as
compared to Ova
GAr-Ova EBNA1 c-myc-GAr-Ova
H1299 Human Lung carcinoma 1560.8 561.1 7065.8
Saos-2 Human osteosarcoma 1561.5 N.T. 7066.3
EL4 Mouse lymphoma 861.1 360.8 862.8
B6 Mouse fibroblast 2061.4 561.6 2062.5
Ramos Human Burkitt’s lymphoma 260.3 261.1 6363.3
NIH3T3 Mouse embryonic fibroblast 1561.8 2062.3 1563.4
B16F10 Murine Melanoma 561.7 562.1 561.9
The presentation of SIINFEKL from chicken ovalbumin (Ova) itself or Ova inserted in the EBNA1 coding sequence was detected using the B3Z reporter cells. The
presentation of SIINFEKL from Ova or from an EBNA1 construct that lacks the GAr sequences (EBNA1DGA) was given the arbitrary value of 100%. The right column
shows the effect of the c-myc IRES on GAr-dependent inhibition of antigen presentation in cell lines from different origins. The table shows data from at least three
experiments and SD. The c-myc IRES overrides GAr-dependent antigen presentation in human derived cell lines only. (N.T. = not tested).
doi:10.1371/journal.ppat.1001151.t001
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PLoS Pathogens | www.plospathogens.org 8 October 2010 | Volume 6 | Issue 10 | e1001151Figure 4. Domain 1 of the c-myc IRES is responsible for the effect of the c-myc IRES on GAr-dependent translation control. A)
Cartoons illustrating the predicted structure and functional domains of the human c-myc IRES and domains 1 and 2 and the ribosome entry window
are indicated. B) Domain 1 was deleted while retaining the ribosome entry window and domain 2 (Dc-myc IRES). C) Autoradiograph of
35S-
methionine metabolic pulse labelling and presentation of SL8 derived from the indicated constructs in H1299 cells. Insertion of the Dc-myc IRES in
the 59UTR of the GAr-Ova mRNA (Dc-myc-GAr-Ova) does not restore translation as compare to the intact c-myc IRES (c-myc-GAr-Ova). Neither Dc-myc
IRES nor c-myc IRES affect translation when inserted in the 59UTR of Ova alone. Data are representative of three or more independent experiments
with SD.
doi:10.1371/journal.ppat.1001151.g004
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PLoS Pathogens | www.plospathogens.org 9 October 2010 | Volume 6 | Issue 10 | e1001151Figure 5. The rate of mRNA translation initiation directly correlates with the amount of antigen presented from a given mRNA. A) A
30 amino acid GAr sequence from the EBV-encoded EBNA1was fused to the N-terminus of Ova (30GAr-EBV-Ova). The GAr sequence from the EBNA1-
like protein of the Papio virus carries four single inserted serine residues (30GAr-Papio-Ova). B) Autoradiograph of a 30 minutes
35S-methionine pulse
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effect [17]. The LANA-1 of Kaposi’s sarcoma virus is also believed
to use a similar mechanism but with a different repeat sequence
[18]. Hence, several viruses might use a similar concept but
different sequences. This makes it more difficult to predict how
wide spread this type of mRNA translation control is among
viruses but it indicates that the strategy to escape the MHC class I
pathway by manipulating mRNA translation initiation applies to
several viruses and is not restricted to the EBV.
The GAr acts in cis and offers a unique opportunity to study the
relationship between antigen presentation, protein stability and
mRNA translation without the addition of general chemical
inhibitors of protein synthesis or degradation that might have
indirect or unspecific effects. By making minimal changes to the
GAr amino acid sequence we have shown that we can fine tune
translation initiation of the mRNAs and, as far as we are aware,
there are no other systems described that allow this. The GAr
consists of single alanines disrupted by one, two or three glycines.
Disruption of the GAr by two alanines next to each other on three
locations is sufficient to reduce the translation and antigen
presentation inhibitory effect of 30 amino acids GAr sequence
by approximately 50%. Introduction of two serines on two
locations has a more disruptive effect and reduces its effect with
approximately 75%. This demonstrates a close correlation
between the rate of mRNA translation initiation and MHC class
I restricted antigen presentation that has consequences for
understanding the source of antigenic peptides for the MHC class
I pathway. These results are in line with other studies suggesting
that protein stability does not affect antigen presentation [40] and
indicates that a fundamental part of the immune system’s capacity
to detect virus-infected host cells is reliant on the mechanism of
viral mRNA translation, as opposed to any features linked to the
actual viral proteins. This supports the notion that MHC class I
restricted immune surveillance is in fact directly correlated with
the mechanisms that regulate protein synthesis and not protein
degradation and supports the model where it is in fact the presence
of mRNA, and not the full length proteins, that is surveilled by the
MHC class I pathway [41]. This opens up for novel ways of
interpreting viral control of mRNA translation and new approaches
for therapeutic intervention aimed at virus associated diseases. These
results also have broader implications in the understanding of the
peptide selection process and will allow the prediction of antigenic
peptide production from specific mRNAs that has implications for
generating more efficient DNA vaccines and potentially also for
better understanding of dysregulated antigen presentation in
autoimmune disease and the generation of self tolerance.
label. C) Presentation of SL8 derived from corresponding constructs in EL4 cells. D) The p53 protein is targeted for the ubiquitin-dependent
degradation pathway by the E3 ligase MDM2 [42]. Fusion of the Papio GAr to p53 results in an accumulation of polyubiquitinated products in the
presence of MDM2, showing that the Papio GAr retains the capacity to affect protein degradation [24]. E) The GAr sequence consists of single
alanines separated by one, two or three glycines. Introducing 2 alanines (GCC) next to each other on 3 separate places (32GAr-3A-Ova) does not alter
the overall GC content of the RNA sequence. F) Introducing a single serine next to an alanine at two locations (31GAr-2S-Ova) is more disruptive in
terms of mRNA translation as compared with the 32GAr-3A-Ova (left, upper panel). The corresponding effect on antigen presentation is shown in the
graph below. The right graph shows the arbitrary values of the rate of mRNA translation initiation and antigen presentation. Data are representative
of three or more independent experiments and values are shown with SD. Cells were transfected with the indicated constructs before split and tested
separately for antigen presentation or synthesis.
doi:10.1371/journal.ppat.1001151.g005
Figure 6. Antigenic peptides (A.P.) can be derived from the main open reading frame as well as cryptic peptides from alternative
reading frames (yellow) and from the 39UTR (pink) [25]. The nascent GAr polypeptide (red) of the EBNA1 prevents translation initiation
throughout the entire mRNA, including its own reading frame and cryptic peptides. This allows the EBV to evade the MHC class I restricted antigen
presentation of peptides from the EBNA1 message and helps the virus to evade the immune system. The GAr also prevents the synthesis of the
EBNA1 full length protein but its long half life ensures that functional levels of EBNA1 are expressed.
doi:10.1371/journal.ppat.1001151.g006
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Cell culture and transfection
The murine lymphoma cell line EL4 (H-2K
b) and B3Z cell line
were maintained in complete medium, consisting of RPMI-1640
medium supplemented with 10% heat-inactivated fetal calf serum
(FCS), 25 mM Hepes-buffer solution (Gibco-BRL, Santa Clara,
CA), 100 IU/ml penicillin and streptomycin (Gibco-BRL), 2 mM
L-glutamine (Gibco-BRL), 2 mM sodium pyruvate solution
(Gibco-BRL), 2 mM non-essential amino acid solution (Gibco-
BRL), and 0.5 mMo f2 - b mercaptoethanol (2-bME) (Sigma-
Aldrich, St. Louis, MO). Transient transfections of EL4 cells were
performed by electroporation using a BMX pulser Bio-Rad Gene
Pulser II (Bio Rad, Hercules, CA) at 260 mV in a 0.4 cm Bio-Rad
electroporation cuvette. EL4 cells were washed once in washing
medium, consisting of RPMI medium 1640 supplemented with
2% heat-inactivated fetal calf serum (FCS), 25 mM Hepes-buffer
solution (Gibco-BRL), 100 units/ml penicillin, and and 100 mg/ml
streptomycin (Gibco-BRL), 2 mM L-glutamine (Gibco-BRL),
2 mM sodium pyruvate solution (Gibco-BRL), 2 mM non-
essential amino acid solution (Gibco-BRL), and 0.5 mMo f2 -
bME (Sigma Chemical). The cells were then suspended in
complete medium at a concentration of 7.5610
6/ml. 8 mgo f
plasmid were inoculated with 3610
6 cells in the electroporation
cuvette. Immediately after electroporation, the cells were trans-
ferred to a 6-well plate with 3 ml of complete media. Human cell
lines were cultivated under standard conditions in RPMI medium
1640 (H1299 and Saos-2), each containing 10% FCS, 2 mM L-
glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin.
Cells were seeded in 6-well plates at a density of 1.75610
5 cells/
well. The following day the cells were cotransfected with 1 mg total
of expression plasmids along with 3 ml of Genejuice according to
the manufacturer’s protocol (Merck Biosciences, Darmstadt,
Germany).
Electrophoresis and western blotting
Following separation on 12% SDS-PAGE, proteins were
transferred to 0.45 mm nitrocellulose membranes, and blots were
blocked for 1 hour at room temperature with a 5% skim milk in
TBS solution consisting of 20 mM Tris, 500 mM NaCl, 0.1%
Tween 20, pH 7.5. Blots were incubated overnight at 4uC with
anti-EBNA1 mouse monoclonal antibody (OT1X) (1:1000) or
polyclonal anti-GA antibody (1:500), raised against the Gly-Ala
sequence of EBNA1 protein or a monoclonal actin antibody
(1:1000) Chemicon International (Temecula, CA) or anti-p53
rabbit polyclonal antibody (CM-1). The membranes were washed
before incubated with horseradish peroxidase-conjugated rabbit
anti-mouse or mouse anti-rabbit immunoglobulin antibody
(1:5000) for another 1 h and detected using ECL (Amersham
Bioscience). The ECL signal was quantified using CCD camera
and associated software (Vilber Lourimat, France). Pre-stained
molecular markers were from Fermenta (Ontario, Canada).
Plasmid constructions
All plasmids were generated using standard procedures. Restric-
tionenzymes,T4DNAligaseandcalfintestinalalkalinephosphatase
were obtained from New England Biolabs (Ipswich, MA). Purified
synthetic oligonucleotides were obtained either from MWG biotech
(Ebersberg, Germany) or Eurogentec. Routine plasmid maintenance
was carried out in DH5a and TOP10 bacteria strains.
The EBNA1 and EBNA1DGA were generated using oligonu-
cleotide pairs 59AGTATAATCAACTTTGAAAAACTCTGA-
GAAG39 and 59CTTCTCAGAGTTTTTCAAAGTTGATTA-
TACT39, encoding the SL8 peptide, inserted into the unique
Bstx1 site found in EBNA1 sequence, right after the GAr
sequence.
The GFP-1 construct was prepared using oligonucleotide pairs
59AATTCTGAATGAGTATAATCAACTTTGAAAAACTCT-
GAT39 and 59CTAGATCAGAGTTTTTCAAAGTTGATTA-
TACTCATTCAG39, encoding the SL8 peptide, inserted into the
EcoR1/Xba1 sites of EGFP-C2 vector (BD Biosciences Clontech,
Palo Alto, CA). The GAr-1 construct was made using the same
oligonucleotide pairs inserted in the 39UTR of the GAr, itself
cloned into the pCDNA-3 vector (Invitrogen, Carlsbad, CA). The
GFP-2 and GAr-2 constructs were made in the same way using the
oligonucleotide pairs 59AATTCCTGAATGAGTATAATCA-
ACTTTGAAAAACTCTGAT39 and 59CTAGATCAGAGTT-
TTTCAAAGTTGATTATACTCATTCAGG39. The different
GAr-2 constructs were prepared by mutating the AUG codon in
GCC or GGC using standard procedures. The GFP-3 and GAr-3
constructs were prepared using the oligonucleotide pairs 59AATT-
CAGTATAATCAACTTTGAAAAACTCTGAT39and 59CTA-
GATCAGAGTTTTTCAAAGTTGATTATACTG39 and insert-
ed in the same vectors.
The c-myc IRES cDNA was obtained from Dr. A.C. Prats
(INSERM U589, France). The pCDNA3-Ova and pCDNA3-
GAr-Ova constructs were obtained as described previously [20].
c-myc-Ova, c-myc-GAr-Ova and c-myc-GAr-2 were generated by
amplification of full length human c-myc IRES by polymerase
chain reaction (PCR), using a 59 sense primer containing a
BamH1 site 59CGGATCCACTAGAACTCGCTGTAGTAA-
TTC39 and a 39 antisense primer 59TCCGGATCCGCGGGAG-
GCTGCTGG 39 containing another BamH1 site. The fragment
was cloned into the 59UTR digested pCDNA3-Ova, pCDNA3-
GAr-Ova and pCDNA3-GAr-2 constructs.
The 30GAr-EBV-Ova construct was made by replacing the full-
length GAr sequence in the Gar-Ova construct with an
oligonucleotide sequences corresponding to 30 amino acids of
the GAr. The same approach was used to produce 32GAr3A-Ova,
31GAr2S-Ova and 30GAr-Papio-Ova.
Metabolic cell labeling and immunoprecipitation
All mRNA translation assays were carried out in H1299 cells
transfected with indicated constructs. Transfected cells were
cultured for 36 hours before treated with 20 mM MG132 for
one hour in methionine free medium containing 2% dialysed FCS.
0.15 mCi/ml of [
35S] methionine (Perkin Elmer, Boston, USA)
was added in the presence of proteasome inhibitor and the cells
were harvested at indicated time points using a rubber policeman
after 2x washing in cold PBS. Cell pellets were snap frozen at
280uC before lysed in PBS containing 1% NP40 and Complete
protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim,
Germany) at 4uC. Lysates were centrifuged for 15 minutes at
14.000 rpm and pre-cleared by addition of mouse sera and protein
G sepharose. An equal amount of total protein was incubated with
specific antibodies for 4 hours at 4uC before the immune
complexes were recovered using protein G sepharose. The
proteins were separated on precast Bis-Tris 4–12% SDS-PAGE
(Invitrogen) and the amount of labelled protein was visualized by
autoradiography and the relative amount of protein synthesis was
determined using phosphoimager.
T-cell assay
EL4-Kb restricted cells (5610
4) expressing the indicated
constructs for 48 h were washed in medium and cultured with
5610
4 B3Z T cell hybridoma for at least 20 h in 96-well plates. T
cell assays in human H1299 cell lines were done by co-transfecting
the Kb expression vector together with the reporter construct. The
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+ T cell hybridoma expresses LacZ in response to
activation of T cell receptors specific for the SIINFEKL peptide
(OVA-immunodominant peptide) in the context of H-2K
b MHC
class I molecules. The cells were then harvested and washed 2
times with 1X cold PBS prior to lysis in 0.2% TritonX-100, 0.5M
K2HPO4, 0.5M KH2PO4 for 5 min on ice. The lysates were
centrifuged for 10 min and 25 ml of supernatant from each well
were transferred into 96-well optiplate counting plates (Packard
Bioscience, Randburg, SA). The plates were incubated for 1 hour
at room temperature, protected from light and tested for b-
Galactosidase activity using the Luminescence assay (BD Biosci-
ences Clontech) on a FLUOstar OPTIMA (BMG LABTECH
Gmbh, Offenburg, Germany). The results were expressed in
counts per seconds (CPS) or in relative light units (RLU). The
peptides SIINFEKL (corresponding to ovalbumin amino acids
258–276) was purchased from Eurogentec (Seraing, Belgium).
Northern blotting analysis
Total RNA was isolated from EL4 cells. After separation on
agarose gels, the RNA was transferred to nylon filter (Hybond-N+;
Amersham Bioscience). An oligonucleotide probe corresponding
to the SIINFEKL sequence was previously labelled with [
32P]ATP
using the Ready-to-Go kit (Amersham Bioscience). After baking
the membrane at 80uC for 2 h, the RNA was hybridized overnight
with the probe at 42uC in PerfectHyb Hybridization Solution
(TOYOBO, Tokyo, Japan). The membranes were washed twice
for 5 min in 16 sodium chloride/sodium citrate (SSC : 0.15 M
NaCl, 15 mM sodium citrate, pH 7.0) that contained 0.1% SDS
at room temperature and twice for 1 h in 16SSC that contained
0.1% SDS at 55uC. The RNA was visualized by autoradiography.
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